[
  {
    "ts": null,
    "headline": "Why Pfizer Inc. (PFE) is One of the Best Affordable Stocks Under $30",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the best affordable stocks under $30. Pfizer Inc. (NYSE:PFE) announced on January 10 positive results from Cohort 3, which is a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® in combination with cetuximab and FOLFIRI in patients with previously untreated metastatic colorectal cancer with a BRAF V600E […]",
    "url": "https://finnhub.io/api/news?id=2abdc9ab1c2df162d72524955c8023c1cfaa57b1debc9a811903c42df2b363b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768495201,
      "headline": "Why Pfizer Inc. (PFE) is One of the Best Affordable Stocks Under $30",
      "id": 138122795,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the best affordable stocks under $30. Pfizer Inc. (NYSE:PFE) announced on January 10 positive results from Cohort 3, which is a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® in combination with cetuximab and FOLFIRI in patients with previously untreated metastatic colorectal cancer with a BRAF V600E […]",
      "url": "https://finnhub.io/api/news?id=2abdc9ab1c2df162d72524955c8023c1cfaa57b1debc9a811903c42df2b363b7"
    }
  },
  {
    "ts": null,
    "headline": "Will DefenCath Continue to Aid CorMedix's Top Line in Q4 Earnings?",
    "summary": "CRMD's DefenCath, the only FDA-approved antimicrobial catheter lock, saw higher outpatient dialysis use in the fourth quarter, likely driving revenues.",
    "url": "https://finnhub.io/api/news?id=21d26c99abb1b74216c4fc6e76b55af7973103941a08a65802e726d42796613a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768484280,
      "headline": "Will DefenCath Continue to Aid CorMedix's Top Line in Q4 Earnings?",
      "id": 138121689,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "CRMD's DefenCath, the only FDA-approved antimicrobial catheter lock, saw higher outpatient dialysis use in the fourth quarter, likely driving revenues.",
      "url": "https://finnhub.io/api/news?id=21d26c99abb1b74216c4fc6e76b55af7973103941a08a65802e726d42796613a"
    }
  },
  {
    "ts": null,
    "headline": "Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade",
    "summary": "Jan 15 (Reuters) - Boston Scientific is buying medical equipment maker Penumbra in a deal valued at about $14.5 billion, to expand its vascular pipeline.",
    "url": "https://finnhub.io/api/news?id=bbfd391d9f8f10e71e49dace0086a3bd81f1b55ce02d42df5ea273c7dd6618c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768479722,
      "headline": "Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade",
      "id": 138120717,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Jan 15 (Reuters) - Boston Scientific is buying medical equipment maker Penumbra in a deal valued at about $14.5 billion, to expand its vascular pipeline.",
      "url": "https://finnhub.io/api/news?id=bbfd391d9f8f10e71e49dace0086a3bd81f1b55ce02d42df5ea273c7dd6618c5"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: The Most Intriguing Value Play Of 2026",
    "summary": "Pfizer: The Most Intriguing Value Play Of 2026",
    "url": "https://finnhub.io/api/news?id=9889cc6cd2341988bf46a7e8ebc0bf9ecfd15292636be55cfacda8e7e852fbb5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768467513,
      "headline": "Pfizer: The Most Intriguing Value Play Of 2026",
      "id": 138120969,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=9889cc6cd2341988bf46a7e8ebc0bf9ecfd15292636be55cfacda8e7e852fbb5"
    }
  },
  {
    "ts": null,
    "headline": "3SBio Sees More Business Development Deals",
    "summary": "Tony He, CFO of the Chinese biopharmaceutical firm 3SBio, discusses his outlook for dealmaking and the progress of a record licensing deal the company struck with Pfizer last year. He speaks on \"Bloomberg: The China Show\" from San Francisco, where the JPMorgan Healthcare Conference is taking place.",
    "url": "https://finnhub.io/api/news?id=f963582c804e948817594323a7b34b77cd63f709fa8c1be01ff8b7bdce6c9609",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768455872,
      "headline": "3SBio Sees More Business Development Deals",
      "id": 138118370,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Tony He, CFO of the Chinese biopharmaceutical firm 3SBio, discusses his outlook for dealmaking and the progress of a record licensing deal the company struck with Pfizer last year. He speaks on \"Bloomberg: The China Show\" from San Francisco, where the JPMorgan Healthcare Conference is taking place.",
      "url": "https://finnhub.io/api/news?id=f963582c804e948817594323a7b34b77cd63f709fa8c1be01ff8b7bdce6c9609"
    }
  }
]